<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE- acetaminophen, caffeine and dihydrocodeine bitartrateÂ tabletÂ </strong><br>MIKART, INC.<br></p></div>
<h1>Acetaminophen, Caffeine and Dihydrocodeine Bitartrate* Tablets CIII<br>712.8 mg/60 mg/32 mg</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_8D1CD848-EE99-4E36-B40F-0FA605CAF926"></a><a name="section-2"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
<p>Code 790Z00</p>
<p>Rev. 02/99</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_ID_96EF4BF4-CA91-4A2A-90C5-38E594E721FB"></a><a name="section-3"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Acetaminophen, Caffeine and Dihydrocodeine Bitartrate Tablets are supplied in tablet form for oral administration.</p>
<p>Each tablet contains:</p>
<p>Acetaminophen..........................................................712.8 mg</p>
<p>Caffeine.....................................................................60 mg</p>
<p>Dihydrocodeine Bitartrate*..........................................32 mg</p>
<p>(*Warning: May be habit forming)</p>
<p>Acetaminophen (4'-hydroxyacetanilide), a slightly bitter, white, odorless, crystalline powder, is a non-opiate, non-salicylate analgesic and antipyretic. It has the following structural formula:</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3AD82B67-F041-46DF-8518-10DEBC35A5ED&amp;name=acetaminophen_caffeine_dihydrocodeine-01.jpg"></div>
<p>C<span class="Sub">8</span>H<span class="Sub">9</span>NO<span class="Sub">2 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â </span>M.W. = 151.17</p>
<p>Caffeine (1,3,7-trimethylxanthine), a bitter, white powder or white-glistening needles, is a central nervous system stimulant. It has the following structural formula:</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3AD82B67-F041-46DF-8518-10DEBC35A5ED&amp;name=acetaminophen_caffeine_dihydrocodeine-02.jpg"></div>
<p>C<span class="Sub">8</span>H<span class="Sub">10</span>N<span class="Sub">4</span>O<span class="Sub">2</span> (anhydrous)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â M.W. = 194.19</p>
<p>Dihydrocodeine bitartrate (4,5Î±-Epoxy-3-methoxy-17-methylmorphinan-6Î±-ol (+)-tartrate), an odorless, fine white powder is an opioid analgesic. It has the following structural formula:</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3AD82B67-F041-46DF-8518-10DEBC35A5ED&amp;name=acetaminophen_caffeine_dihydrocodeine-03.jpg"></div>
<p>C<span class="Sub">18</span>H<span class="Sub">23</span>NO<span class="Sub">3â€¢</span>C<span class="Sub">4</span>H<span class="Sub">6</span>O<span class="Sub">6</span>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â M.W. = 451.48</p>
<p>In addition, each tablet contains the following inactive ingredients:  colloidal silicon dioxide, crospovidone, magnesium stearate, microcrystalline cellulose, povidone, pregelatinized starch, stearic acid, D&amp;C Red #27 Aluminum Lake, D&amp;C Red #30 Aluminum Lake, and FD&amp;C Blue #1 Aluminum Lake.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_ID_A2B49D2E-D858-485D-83FA-AED196FCDA2E"></a><a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Acetaminophen, Caffeine and Dihydrocodeine Bitartrate Tablets contain dihydrocodeine which is a semi-synthetic narcotic analgesic related to codeine, with multiple actions qualitatively similar to those of codeine; the most prominent of these involve the central nervous system and organs with smooth muscle components. The principal action of therapeutic value is <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>.</p>
<p>This combination product also contains acetaminophen, a non-opiate, non-salicylate analgesic, and antipyretic.</p>
<p>This combination product contains caffeine as an analgesic adjuvant. Caffeine is also a central nervous system and cardiovascular stimulant.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_ID_3AC516C2-139B-4307-B018-2ABCD5B3CD14"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Acetaminophen, Caffeine and Dihydrocodeine Bitartrate Tablets are indicated for the relief of moderate to moderately severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_ID_C2CB5502-93D5-4902-9494-AD5E8E1D3C75"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">This combination product is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to dihydrocodeine, codeine, acetaminophen, caffeine, or any of the inactive components listed above, or in any situation where opioids are contraindicated including significant <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (in unmonitored settings or in the absence of resuscitative equipment), acute or severe bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span>, and <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_ID_415E1940-D700-4D82-B576-792EE4BC0908"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_0623016F-986B-4891-B0D0-908626AF4442"></a><a name="section-7.1"></a><p></p>
<h2>Usage in Ambulatory Patients</h2>
<p class="First">Dihydrocodeine may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_B2ADE471-E2BE-45EC-B1CE-3E8AC9F647A2"></a><a name="section-7.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> is the most dangerous acute reaction produced by opioid agonist preparations, although it is rarely severe with usual doses. Opioids decrease the <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>, tidal volume, minute ventilation, and sensitivity to <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span>. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> occurs most frequently in elderly or debilitated patients, usually after large initial doses in non-tolerant patients, or when opioids are given in conjunction with other agents that depress respiration. This combination product should be used with caution in patients with significant <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> or <span class="product-label-link" type="condition" conceptid="4307356" conceptname="Cor pulmonale">cor pulmonale</span> and in patients with a substantially decreased respiratory reserve, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span>, or <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. In such patients alternative non-opioid analgesics should be considered, and opioids should be administered only under careful medical supervision at the lowest effective dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_C3D8CB16-4F43-4736-A96D-60EB224BB19B"></a><a name="section-7.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span></h2>
<p class="First">This combination product should be used cautiously in the presence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span> or <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span>. The effects of opioids on pupillary response and consciousness may obscure neurologic signs of increases in intracranial pressure in patients with head injuries. The respiratory depressant effects including <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> retention and secondary elevation of cerebrospinal fluid pressure may be markedly exaggerated in the presence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, intracranial lesions, or other causes of <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_6FFF55CC-939B-448B-8B39-7148038BAD98"></a><a name="section-7.4"></a><p></p>
<h2>Hypotensive Effect</h2>
<p class="First">Dihydrocodeine, like all opioid analgesics, may cause <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in patients whose ability to maintain blood pressure has been compromised by a depleted blood volume or who receive concurrent therapy with drugs such as phenothiazines or other agents which compromise vasomotor tone. Acetaminophen, Caffeine and Dihydrocodeine Bitartrate Tablets may produce <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> in ambulatory patients. This combination product should be administered with caution to patients in circulatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, since vasodilation produced by the drug may further reduce <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and blood pressure.</p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="i4i_dependence_ID_A1FD2F08-BC46-41C3-888C-527B68346A0E"></a><a name="section-7.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug Dependence</span></h2>
<p class="First">Dihydrocodeine can produce <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> of the codeine type and has the potential of being abused (see <a href="#i4i_abuse_dependence_ID_FE3528AF-DAB1-4698-9333-AB65BE66CD0D">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_ID_316A3D9D-D68A-4314-8AF1-E6DA074B9E81"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_ID_34A0FAD7-67EB-4589-81A7-8A845160AFED"></a><a name="section-8.1"></a><p></p>
<h2>General</h2>
<p class="First">Selection of patients for treatment with Acetaminophen, Caffeine and Dihydrocodeine Bitartrate Tablets should be governed by the same principles that apply to the use of similar opioid/non-opioid fixed combination analgesics. As with any such opioid analgesic, the dosing regimen should be adjusted for each patient (see <a href="#i4i_dosage_admin_ID_3B9C72A2-3DAF-45CE-861E-65BEA28D4B56">DOSAGE AND ADMINISTRATION</a>). This combination product should be used with caution in elderly or debilitated patients or those with any of the following conditions: acute <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span>; adrenocortical insufficiency (e.g., Addisonâ€™s disease); <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>; central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>; <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span>; decreased respiratory reserve (including <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>, severe <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, <span class="product-label-link" type="condition" conceptid="4307356" conceptname="Cor pulmonale">cor pulmonale</span>, or kyphoscoliosis); <span class="product-label-link" type="condition" conceptid="377830" conceptname="Alcohol withdrawal delirium">delirium tremens</span>; <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>; <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>; <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span>; <span class="product-label-link" type="condition" conceptid="4182596" conceptname="Myxedema">myxedema</span> or <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>; <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> or <span class="product-label-link" type="condition" conceptid="195590" conceptname="Urethral stricture">urethral stricture</span>; and toxic <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. The benefits and risks of using opioids in patients taking monoamine oxidase inhibitors and in those with a history of drug abuse should be carefully considered. The administration of an analgesic containing an opioid may obscure the diagnosis or clinical course in patients with acute abdominal conditions. This combination product may aggravate <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> in patients with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span> and, like all opioids, may induce or aggravate <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in some clinical settings. </p>
<p>Acetaminophen is relatively non-toxic at therapeutic doses, but should be used with caution in patients with severe renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>. </p>
<p>Care should be observed when using large doses of acetaminophen in malnourished patients or those with a history of chronic <span class="product-label-link" type="condition" conceptid="433753" conceptname="Alcohol abuse">alcohol abuse</span> because they may be more susceptible to <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">hepatic damage</span> similar to that observed with toxic overdosage.</p>
<p>Caffeine in high doses may produce central nervous system and cardiovascular stimulation and <span class="product-label-link" type="condition" conceptid="4318531" conceptname="Gastrointestinal irritation">gastrointestinal irritation</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_drug_interaction_ID_8A2382B4-FEB4-41EB-B94C-E904E42315BC"></a><a name="section-8.2"></a><p></p>
<h2>Drug-Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_AAEFE3D9-C596-41E0-8B50-8EE8D8D8B89E"></a><a name="section-8.2.1"></a><p></p>
<h3>Dihydrocodeine with Other Central Nervous System Depressants</h3>
<p class="First">Patients receiving other opioid analgesics, sedatives or hypnotics, muscle relaxants, general anesthetics, centrally acting anti-emetics, phenothiazines or other tranquilizers, or alcohol concomitantly with this combination product may exhibit additive depressant effects on the central nervous system. When such combined therapy is contemplated, the dosage of one or both agents should be reduced.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_87F54040-6D23-490C-9CA3-A804F7690FFF"></a><a name="section-8.2.2"></a><p></p>
<h3>Dihydrocodeine with Monoamine Oxidase Inhibitors</h3>
<p class="First">Dihydrocodeine, like all opioid analgesics, interacts with monoamine oxidase inhibitors causing central nervous system excitation and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_7A0FF8E3-8D4D-42A3-B24F-820EF2ACD226"></a><a name="section-8.2.3"></a><p></p>
<h3>Dihydrocodeine with Mixed Agonist/Antagonist Opioid Analgesics </h3>
<p class="First">Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) may reduce the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> of this combination product.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_39AAA48F-A1BE-4CAE-BA60-595FCCC0F5E0"></a><a name="section-8.2.4"></a><p></p>
<h3>Acetaminophen-Drug Interactions</h3>
<p class="First">Chronic and excessive consumption of alcohol may increase the hepatotoxic risk of acetaminophen. The potential for hepatotoxicity with acetaminophen also may be increased in patients receiving anticonvulsants that induce hepatic microsomal enzymes (including phenytoin, barbiturates, and carbamazepine) or isoniazid. Chronic ingestion of large doses of acetaminophen may slightly potentiate the effects of warfarin- and indandione-derivative anticoagulants. Severe <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span> is possible in patients receiving acetaminophen concomitantly with phenothiazines.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_BD881F95-AC99-47D4-8AC7-0C0FD0675DA4"></a><a name="section-8.2.5"></a><p></p>
<h3>Caffeine-Drug Interactions</h3>
<p class="First">Caffeine may enhance the cardiac inotropic effects of beta-adrenergic stimulating agents.  Coadministration of caffeine and disulfiram may lead to a substantial decrease in caffeine clearance. Caffeine may increase the metabolism of other drugs such as phenobarbital and aspirin. Caffeine accumulation may occur when products or foods containing caffeine are consumed concomitantly with quinolones such as ciprofloxacin.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_ID_7DA03587-D630-4465-A945-0D59B1D87059"></a><a name="section-8.3"></a><p></p>
<h2>Information for Patients/Caregivers</h2>
<p class="First">Patients receiving Acetaminophen, Caffeine and Dihydrocodeine Bitartrate Tablets should be given the following information:</p>
<ol>
<li>Patients should be advised that Acetaminophen, Caffeine and Dihydrocodeine Bitartrate Tablets may impair the mental or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery.</li>
<li>Patients should be advised to report adverse experiences occurring during therapy.</li>
<li>Patients should be advised not to adjust the dose of Acetaminophen, Caffeine and Dihydrocodeine Bitartrate Tablets without consulting the prescribing professional.</li>
<li>Patients should not combine Acetaminophen, Caffeine and Dihydrocodeine Bitartrate Tablets with alcohol or other central nervous system depressants (sleep aids, tranquilizers) except by the orders of the prescribing physician, because additive effects may occur.</li>
<li>Women of childbearing potential who become, or are planning to become, pregnant should be advised to consult their physician regarding the effects of analgesics and other drug use during pregnancy on themselves and their unborn child.</li>
<li>Patients should be advised that Acetaminophen, Caffeine and Dihydrocodeine Bitartrate Tablets are a potential drug of abuse. They should protect it from <span class="product-label-link" type="condition" conceptid="4087298" conceptname="Theft">theft</span>, and it should never be given to anyone other than the individual for whom it was prescribed.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_ID_C13A0692-5653-4208-85BC-2AC3231DAAD7"></a><a name="section-8.4"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_ID_753699BF-5255-4DA1-8225-7A91C9547849"></a><a name="section-8.4.1"></a><p></p>
<h3>Teratogenic Effects - Pregnancy Category C. </h3>
<p class="First">Animal reproduction studies have not been conducted with Acetaminophen, Caffeine and Dihydrocodeine Bitartrate Tablets. It is also not known whether this combination product can cause fetal harm when administered to pregnant women or can affect reproduction capacity in males and females. This combination product should be given to a pregnant woman only if clearly needed, especially during the first trimester.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_ID_00C61EBC-B618-4270-84DA-C3BFA6A62858"></a><a name="section-8.5"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">Acetaminophen, Caffeine and Dihydrocodeine Bitartrate Tablets are not recommended for use by women during and immediately before labor and delivery because oral opioids may cause <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the newborn. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_ID_EA6B0673-CB85-45A2-85A9-053D16E0ECEA"></a><a name="section-8.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Dihydrocodeine bitartrate, acetaminophen and caffeine are excreted in breast milk in small amounts, but the significance of their effects on nursing infants is not known. Because of the potential for serious adverse reactions in nursing infants from this combination product, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_ID_7B623213-FB3B-48BD-B8C1-73A1898625A4"></a><a name="section-8.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness of Acetaminophen, Caffeine and Dihydrocodeine Bitartrate Tablets in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_ID_1C6450CD-4DB2-4EDF-9A51-31DAD849CF62"></a><a name="section-8.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Acetaminophen, Caffeine and Dihydrocodeine Bitartrate Tablets should be given with caution to the elderly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_25A0FEA0-BC81-46AF-80C8-7CD48BF89F75"></a><a name="section-8.9"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Acetaminophen, Caffeine and Dihydrocodeine Bitartrate Tablets should be given with caution to patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>. Since dihydrocodeine is metabolized by the liver and since acetaminophen potentially causes hepatotoxicity, the effects of this combination product should be monitored closely in such patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_73DEDFAC-9957-4FA7-88E4-280D8B412367"></a><a name="section-8.10"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Acetaminophen, Caffeine and Dihydrocodeine Bitartrate Tablets should be used with caution and at reduced dosage in the presence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_04627A95-182A-4833-8FB0-3E2248046F38"></a><a name="section-8.11"></a><p></p>
<h2>Pancreatic/<span class="product-label-link" type="condition" conceptid="197917" conceptname="Disorder of biliary tract">Biliary Tract Disease</span></h2>
<p class="First">Opioids may cause <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> of the sphincter of Oddi and should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="197917" conceptname="Disorder of biliary tract">biliary tract disease</span> including <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_ID_D62B3AC9-213E-419B-8CD8-E2F1028EBC79"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_B7906879-81C3-43C0-929B-47D0A708D530"></a><a name="section-9.1"></a><p></p>
<h2>Dihyrocodeine</h2>
<p class="First">The most frequently observed reactions include <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, sedation, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>. With the exception of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, tolerance develops to most of these effects. Other reactions that have been observed with dihydrocodeine or other opioids include <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, <span class="product-label-link" type="condition" conceptid="4009383" conceptname="Cough suppression">cough suppression</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, spasm of biliary tract, and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>. Physical and psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> are possibilities. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> (including <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>), <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">vivid dreams</span>, granulomatous interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, severe <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">narcosis</span> and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> have been reported rarely during dihydrocodeine administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_20E89FB1-E674-4553-86C6-F4326B2C2A42"></a><a name="section-9.2"></a><p></p>
<h2>Acetaminophen</h2>
<p class="First">Acetaminophen in therapeutic doses rarely causes adverse reactions. The most serious adverse reaction is hepatotoxicity from overdosage (see <a href="#i4i_overdosage_ID_6832DDCE-EAD6-4514-8517-EF3A950EC0A6">OVERDOSAGE</a>). <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> have been reported in patients receiving acetaminophen or Ï?-aminophenol derivatives. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> including urticarial or erythematous <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, or <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> are rare.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_89293D4F-F66D-4A7D-A8DD-BE508575032A"></a><a name="section-9.3"></a><p></p>
<h2>Caffeine</h2>
<p class="First">Adverse reactions associated with caffeine use include <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="442077" conceptname="Anxiety disorder">anxiety neurosis</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="4136244" conceptname="Feeling tense">tenseness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">extrasystoles</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4319270" conceptname="Scintillating scotoma">scintillating scotoma</span>, and <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="i4i_abuse_dependence_ID_FE3528AF-DAB1-4698-9333-AB65BE66CD0D"></a><a name="section-10"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">This combination product is subject to the provisions of the Controlled Substance Act, and has been placed in Schedule III. </p>
<p>Dihydrocodeine can produce <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> of the codeine type and therefore has the potential of being abused. Like other opioid analgesics, dihydrocodeine may produce subjective effects other than <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> (e.g., <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, relaxation), which may contribute to abuse by some patients. Psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and tolerance may develop upon repeated administration of dihydrocodeine, and it should be prescribed and administered with the same degree of caution appropriate to the use of other oral opioid analgesic medications. Symptoms of dihydrocodeine withdrawal consist of <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> and <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>. </p>
<p>Prolonged, high intake of caffeine may produce tolerance and <span class="product-label-link" type="condition" conceptid="4036424" conceptname="Drug tolerance">habituation</span>. Physical signs of withdrawal, such as <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, irritation, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> may occur upon abrupt discontinuation.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_ID_6832DDCE-EAD6-4514-8517-EF3A950EC0A6"></a><a name="section-11"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Following an acute overdosage with Acetaminophen, Caffeine and Dihydrocodeine Bitartrate Tablets, toxicity may result from the dihydrocodeine, acetaminophen, or, less likely, caffeine component. An <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is a potentially lethal polydrug <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> situation, and consultation with a regional poison control center is recommended. A listing of the poison control centers can be found in standard references such as the <span class="Italics">Physicianâ€™s Desk Reference<span class="Sup">Â®</span>.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_0F829035-CE6A-44FF-BAED-0AA1A600F815"></a><a name="section-11.1"></a><p></p>
<h2>Signs and Symptoms and Laboratory Findings</h2>
<p class="First">Toxicity from <span class="Italics">dihydrocodeine</span> is typical of opioids and includes pinpoint pupils, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, and <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>, <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur. A single case of acute <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> associated with an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of dihydrocodeine has been reported. With <span class="Italics">acetaminophen</span>, dose-dependent potentially fatal <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> is the most serious adverse effect. <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">Renal tubular necrosis</span>, <span class="product-label-link" type="condition" conceptid="380688" conceptname="Hypoglycemic coma">hypoglycemic coma</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> may occur. Early symptoms of hepatotoxicity include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">general malaise</span>. Clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours after ingestion. Acute <span class="Italics">caffeine</span> <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> may cause <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">extrasystoles</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. </p>
<p>Because <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> information on this combination product is limited, it is unclear which of the signs and symptoms of toxicity would manifest in any particular <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> situation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_F1EDECD2-8D01-4F3E-9FD6-6EC2C36E858D"></a><a name="section-11.2"></a><p></p>
<h2>Treatment</h2>
<p class="First">Immediate treatment of an overdosage of Acetaminophen, Caffeine and Dihydrocodeine Bitartrate Tablets includes support of cardiorespiratory function and measures to reduce drug absorption. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> should be induced with syrup of ipecac, if the patient is alert and has adequate laryngeal reflexes. Oral activated charcoal should follow. The first dose of charcoal should be accompanied by an appropriate cathartic. Gastric lavage may be necessary. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> is usually hypovolemic and should be treated with fluids. Endotracheal intubation and artificial respiration may be necessary. Peritoneal or hemodialysis may be necessary. If <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span> occurs, Vitamin K should be administered. </p>
<p>A pure opioid antagonist, such as naloxone or nalmefene, is a specific antidote against <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> which results from opioid <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Opioid antagonists should not be given in the absence of clinically significant respiratory or circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> secondary to opioid <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.  They should be administered cautiously to persons who are known, or suspected to be, physically dependent on any opioid agonist including Acetaminophen, Caffeine and Dihydrocodeine Bitartrate Tablets. In such cases, an abrupt or complete reversal of opioid effects may precipitate an acute abstinence syndrome. The prescribing information for the specific opioid  antagonist should be consulted for details of their proper use. </p>
<p>In adults and adolescents, regardless of the quantity of acetaminophen reported to have been ingested, acetylcysteine should be administered immediately if 24 hours or less have elapsed from the reported time of ingestion. It is not advisable to await the plasma concentration determination of acetaminophen before administering acetylcysteine. Serum liver enzyme levels should be measured. Therapy in children involves a similar treatment scheme; however, a regional Poison Control Center should be contacted. </p>
<p>No specific antidote is available for caffeine. In addition to the supportive measures above, administration of demulcents such as aluminum hydroxide gel may diminish <span class="product-label-link" type="condition" conceptid="4318531" conceptname="Gastrointestinal irritation">gastrointestinal irritation</span>. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> may be treated with intravenous diazepam or a barbiturate.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_ID_3B9C72A2-3DAF-45CE-861E-65BEA28D4B56"></a><a name="section-12"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The usual adult dosage is one (1) Acetaminophen, Caffeine and Dihydrocodeine Bitartrate Tablet orally every four (4) hours, as needed. Dosage should be adjusted according to the severity of the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and the response of the patient. No more than one tablet should be taken in a four hour period. No more than five (5) doses, or five (5) tablets should be taken in a 24-hour period.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_ID_F8A40E3B-8CF8-4ECE-AF8F-58E0012C8DFE"></a><a name="section-13"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Acetaminophen, Caffeine and Dihydrocodeine Bitartrate Tablets, containing acetaminophen 712.8 mg, caffeine 60 mg and dihydrocodeine bitartrate* 32 mg, (*Warning: May be habit-forming), are supplied in bottles of 100 tablets NDC 0525-0032-01, and in bottles 500 tablets, NDC 0525-0032-05.  Tablets are lavender, oval-shaped, single-scored and are debossed â€œPALâ€? on one side and â€œ032â€? on the other side.</p>
<p>Store at controlled room temperature, 15Â°-30Â°C (59Â°-86Â°F).  Protect from moisture.</p>
<p>Dispense in a tight, light-resistant container with a child resistant closure. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_D1701389-0CEC-4CD2-B9F5-79ADBB9A357C"></a><a name="section-14"></a><p></p>
<p class="First">Manufactured by:</p>
<p><span class="Bold">MIKART, INC.</span></p>
<p>Atlanta, GA 30318</p>
<p>Rev. 02/99 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Code 790Z00</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATEÂ 		
					</strong><br><span class="contentTableReg">acetaminophen, caffeine and dihydrocodeine bitartrate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0525-0032</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIIIÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ACETAMINOPHEN</strong> (ACETAMINOPHEN) </td>
<td class="formItem"></td>
<td class="formItem">712.8Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>CAFFEINE</strong> (CAFFEINE) </td>
<td class="formItem"></td>
<td class="formItem">60Â mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DIHYDROCODEINE BITARTRATE</strong> (CODEINE) </td>
<td class="formItem"></td>
<td class="formItem">32Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D &amp; C RED # 30 ALUMINUM LAKE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D &amp; C RED #27 ALUMINUM LAKE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD &amp; C BLUE # 1 ALUMINUM LAKE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE (POWDER)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MICROCRYSTALLINE CELLULOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PREGELATINIZED STARCH</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PURPLE (LAVENDER) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">PAL;032</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">false</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0525-0032-05</td>
<td class="formItem">500  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0525-0032-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>MIKART, INC.</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 10/2006<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>9D21D8A9-D428-D80F-8B00-7AB537059950</div>
<div>Set id: 3AD82B67-F041-46DF-8518-10DEBC35A5ED</div>
<div>Version: 1</div>
<div>Effective Time: 20061006</div>
</div>
</div>Â <div class="DistributorName">MIKART, INC.</div></p>
</body></html>
